GlassScriptPhysician profile
Mary M Cherrette
NPI 1225679491
$3,170.50
in general payments reported to CMS, 2019-2025
13 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $581 · 2023: $704 · 2024: $765 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.90 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,215.91 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $666.55 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $480.09 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $418.35 | 2023-2025 | Dupixent |
| Amgen INC. | $115.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Insmed, INC. | $50.15 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.55 | 2023-2025 | Ofev |
| Verona Pharma, INC. | $18.89 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $18.05 | 2023 | Yupelri |
| Breas Medical, INC. | $16.79 | 2024 | Vivo 45 Ls |
| Genentech USA, INC. | $16.10 | 2025 | Xolair |
| Inogen, INC. | $15.88 | 2023 | Inogen One G3 Oxygen Concentrator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cherrette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.